Clinical Trial Update: Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of AGN-241622 in healthy participants and presbyopia patients was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia

Drugs mentioned

• AGN-241622

Snippet

Sponsor: AbbVie | Conditions: Presbyopia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-02-06